INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline

Regeneron Pharmaceuticals, Inc. is facing a securities class action lawsuit following revelations about a Phase 3 clinical trial for its melanoma therapy, Fianlimab in combination with Libtayo. The lawsuit alleges that Regeneron made misleading statements and failed to disclose critical information regarding the trial's progress and the statistical assumptions. The company had expressed optimism about the trial's primary endpoint, progression-free survival (PFS), even characterizing the combination as a "potential blockbuster." However, on April 29, 2026, Regeneron announced a modification to the trial protocol, requiring a minimum 6-month follow-up for all patients, which analysts questioned as a potential sign of insufficient benefit. On May 12, 2026, Regeneron admitted the protocol change was due to "slow event rates" and had been made nearly six months prior. Subsequently, on May 15, 2026, the company reported that the trial did not reach statistical significance for its primary endpoint. The lawsuit claims that Regeneron altered the trial protocol without timely disclosure to mislead investors.